Re: wagner Post# 410 There certainly are opaque reasons for plummet from 28 to under 8... The test accuracy rate seems a good alternative to invasive tests for those not in high risk population. Competitors and vested interests in the status quo of highly invasive tests may have been factor in "alternative" versus "recommended" decision by the review agency. But seems like big financial players were all ready to prey on that outcome as cover to push prices down hugely "overnight" -- apparently in part to take advantage of very low probability options contracts, which also instantly proliferated "overnight" for months into the future. This is an important medical test option -- I hope the company recovers. And the share price back above 10-14.
News 
Market Data 
Discover 
